drugset / Trial / NCT05146284
Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
RandomizedParallel-groupOpen-labelTreatment
Summary
A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of PXL770 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy (AMN).
Timeline
- Start
- 2023-09
- Primary completion
- 2024-09
- Completion
- 2024-09
Outcome
Outcome not reported
Stopped (Business): “Lack of funding to initiate the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PXL770 | Unknown | 250 mg | — |
| Subject | PXL770 | Unknown | 500 mg | — |